Dr. Reva Kakkar Basho, MD

Dr. Basho practices at Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System.

Dr. Basho's NPI, 1508146721, was assigned on August 18, 2011. Dr. Basho graduated from Baylor College Of Medicine in 2010. Dr. Basho's California license number on file is A119414.

Dr. Basho's primary practice is Cedars-Sinai Medical Center, at 8700 Beverly Blvd, Los Angeles, CA 90048 in Los Angeles County. The practice phone is (310) 423-5000.

Dr. Basho's primary practice is Cedars-Sinai Medical Center in Los Angeles, California, part of Cedars-Sinai Health System. The medical group on file is Saint John's Physician Partners.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Basho practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Basho's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Basho is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Basho's licenses on file in 2 states: California and Texas.

Dmand AI lists breast cancer among the conditions Dr. Basho treats.

CMS data shows 146 Medicare services from Dr. Basho across 4 procedure codes in 2024, for 26 Medicare patients. Medicare paid $5,474 for them. Every service was in an office.

CMS counts 26 Medicare patients who saw Dr. Basho in 2024. 75% of them have cancer, and 58% have arthritis. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Basho's median patient age at 54, with 97% women.

In 2022, Dr. Basho wrote 128 Medicare Part D claims. Every claim was for a generic drug. They cover 3 drugs, with $10,683 in total drug cost. In 2021, CMS named 208 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Basho for performance year 2024, reported as part of a group. Dr. Basho accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Basho as offering telehealth.

Dmand AI links 23 papers to Dr. Basho, published from 2016 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Breast Neoplasms, Triple Negative Breast Neoplasms and Antineoplastic Agents. Dr. Basho has published most often in Front Oncol. Dr. Basho's most frequent co-authors are Jennifer K. Litton, MD, Heather Lynn McArthur, MD and Filip Janku, MD, PhD.

Dmand AI links Dr. Basho to 10 clinical trials, 5 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Triple Negative Breast Neoplasms. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Basho that name 2 trials.

CMS Open Payments shows 104 general payments to Dr. Basho from 12 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 78% of the total. AstraZeneca Pharmaceuticals LP paid the most, $46,474. It also lists 12 research payments totaling $37,128 from 2020 to 2025, naming 2 clinical trials.

Dr. Basho graduated from Baylor College Of Medicine in 2010.

Dr. Basho is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.